Elite Pharmaceuticals Q1 FY2027 Revenue Falls 19.5% to $32.4M; Net Income $5.9M
ELTP is trading near its 52-week low of $0.325 (10% above the low).
Summary
Elite Pharmaceuticals reported Q1 FY2027 revenue of $32.4 million, down 19.5% year-over-year, with net income of $5.9 million. The decline reflects lower margins on generic Vyvanse, but results are consistent with recent quarters.
Key Events · Earnings and Guidance · ELTP
-
Q1 FY2027 Revenue Declines 19.5%
Consolidated revenues were $32.4 million, a decrease of $7.9 million from the prior-year quarter, which had the largest quarterly revenue in company history.
-
Operating Income Falls 65%
Income from operations was $7.5 million, down $14.2 million year-over-year, primarily due to lower margins from generic Vyvanse sales.
-
Net Income $5.9 Million
Net income attributable to common shareholders was $5.9 million for the quarter ended June 30, 2026.
-
Results In Line With Recent Quarters
Management noted that while year-over-year comparisons show decreases, results are consistent with the three prior quarters, indicating stabilization.
Analysis · ELTP · Life Sciences
Elite Pharmaceuticals reported Q1 FY2027 revenue of $32.4 million, down 19.5% from the prior-year quarter, which had the largest quarterly revenue in company history. Income from operations fell 65% to $7.5 million, primarily due to lower margins on generic Vyvanse sales. Net income attributable to common shareholders was $5.9 million. The company notes results are in line with the three prior quarters, suggesting stabilization after a competitive market adjustment. A conference call is scheduled for August 14, 2026.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.5% of the 1629 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELTP was trading at $0.36 on OTC in the Life Sciences sector, with a market capitalization of approximately $386.2M. The 52-week trading range was $0.33 to $0.74. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.